Mitsui Chemicals invests in iORGANBIO and partners on cell and organoid manufacturing
Reported by Business Insider and Markets Insider2 sources ↓
iORGANBIO says it received an investment from Mitsui Chemicals through the company’s 321Catalyst venture fund. The companies will combine their technologies to develop human cells and organoids for research and regenerative medicine.
Key points
- Mitsui Chemicals invested in iORGANBIO through its 321Catalyst venture fund
- The companies plan to combine iORGANBIO’s platform with Mitsui’s cell-culture materials
- They will explore drug testing technologies using cells and organoids as alternatives to animal testing
- The investment amount was not disclosed
Sources
Details
The investment was announced by iORGANBIO on Nov. 10, according to the press release carried by Markets Insider. It was made through 321Catalyst, Mitsui Chemicals’ corporate venture capital fund; the amount was not disclosed.
The companies plan to combine iORGANBIO’s platform, which uses AI, single-cell analysis and robotics in an autonomous laboratory, with Mitsui Chemicals’ materials capabilities, including its InnoCell cell-culture plates. They aim to improve the consistency of cells and organoids and produce types that have been difficult to manufacture.
The companies also plan to explore drug-discovery technologies that could complement or replace animal testing, including efficacy and safety assessments using their cells and organoids.
Written from coverage as of